MENLO PARK, CA / ACCESSWIRE / April 30, 2024 / Emmetrope Ophthalmics LLC ("Emmecell"), a clinical-stage biotechnology company pioneering the discovery and development of cell-based therapies for the treatment of serious eye diseases, today announced final dose administration for the last patient in its U.S.
Emmecell Announces First Patient Dosed with EO2002 in US Phase 1 Study in Patients with Corneal Edema prweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prweb.com Daily Mail and Mail on Sunday newspapers.